Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Novel agent ENT-03 demonstrates promising metabolic improvements and safety in first-in-human study, setting stage for further development in …
Phase 3 trial data show promising metabolic improvements and durable weight reduction, expanding potential treatment options for millions.
Cycle Pharmaceuticals’ CEO calls approval “a defining moment for patients, physicians and science—proving unmet metabolic needs can be …
New clinical findings support dapiglutide’s potential as first-in-class injectable therapy; CEO touts “milestone in multi-receptor peptide innovation”.
Mid-stage data reveal safety and efficacy signals supporting potential shift in frontline treatment for higher-risk MDS patients.
Clinical trial results underscore safety and diagnostic accuracy for radiopharmaceutical imaging; Clarity pursues regulatory filings and wider manufacturing …
Combination of ZYNLONTA® and glofitamab (COLUMVI®) shows durable complete responses and manageable safety profile in Phase 1b study.
This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
June 10 sees robust momentum in biotechnology with novel therapeutic developments, advanced clinical trials, key industry events, and …
Already a subscriber? Log in